Cypress Capital Group Has $7.58 Million Stake in Eli Lilly and Company (NYSE:LLY)
Cypress Capital Group boosted its stake in Eli Lilly and Company (NYSE:LLY) by 3.5% during the first quarter, Holdings Channel reports. The institutional investor owned 90,061 shares of the company’s stock after buying an additional 3,058 shares during the period. Eli Lilly and accounts for 1.8% of Cypress Capital Group’s holdings, making the stock its 14th largest position. Cypress Capital Group’s holdings in Eli Lilly and were worth $7,575,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Private Capital Advisors Inc. raised its stake in shares of Eli Lilly and by 9.7% in the first quarter. Private Capital Advisors Inc. now owns 384,564 shares of the company’s stock worth $32,346,000 after buying an additional 34,141 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Eli Lilly and by 3.5% in the first quarter. Bank of Montreal Can now owns 904,360 shares of the company’s stock worth $76,066,000 after buying an additional 30,775 shares in the last quarter. Gradient Investments LLC raised its stake in shares of Eli Lilly and by 8.3% in the first quarter. Gradient Investments LLC now owns 85,342 shares of the company’s stock worth $7,178,000 after buying an additional 6,523 shares in the last quarter. CrestPoint Capital Management LLC raised its stake in shares of Eli Lilly and by 320.7% in the first quarter. CrestPoint Capital Management LLC now owns 12,200 shares of the company’s stock worth $1,026,000 after buying an additional 9,300 shares in the last quarter. Finally, Beutel Goodman & Co Ltd. bought a new stake in shares of Eli Lilly and during the first quarter worth $161,084,000. Institutional investors and hedge funds own 75.61% of the company’s stock.
Shares of Eli Lilly and Company (NYSE LLY) traded down 0.47% during trading on Friday, reaching $81.15. 2,446,392 shares of the company were exchanged. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The stock has a market capitalization of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34. The stock has a 50-day moving average price of $82.91 and a 200-day moving average price of $81.72.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.86 EPS. Analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.56%. Eli Lilly and’s payout ratio is currently 90.04%.
TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/cypress-capital-group-has-7-58-million-stake-in-eli-lilly-and-company-nyselly/1479270.html.
A number of analysts have weighed in on LLY shares. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $92.00 target price on shares of Eli Lilly and in a research report on Tuesday, May 16th. Citigroup Inc. raised their target price on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, April 19th. Jefferies Group LLC restated a “buy” rating and issued a $92.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research report on Saturday, April 29th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research report on Monday, April 17th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the completion of the transaction, the insider now directly owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock valued at $55,845,287 in the last three months. 0.20% of the stock is currently owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.